Biomea Fusion Highlights Initial Data From The First Two Type 1 Diabetes Patients Dosed With BMF-219
Biomea Fusion Highlights Initial Data From The First Two Type 1 Diabetes Patients Dosed With BMF-219
Biomea Fusion 重點介紹了前兩名服用 BMF-219 的 1 型糖尿病患者的初步數據
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes
BMF-219 是一種正在研究的新型共價腦膜抑制劑，開發用於再生產生胰島素的 β 細胞，旨在治癒糖尿病
The first two type 1 diabetes patients enrolled in COVALENT-112 both demonstrated early signs of clinical activity with improved measures of beta-cell function after initial treatment with BMF-219
BMF-219 has been well tolerated by both patients
Open label portion of Phase II COVALENT-112 study readout of 40 patients with type 1 diabetes dosed for 12 weeks with BMF-219 expected in 2024
First type 2 diabetes patient dosed with BMF-219 for 4 weeks in COVALENT-111 being taken off background therapy (metformin) after week 40, displaying improved glycemic...
入組 COVALENT-112 的前兩名 1 型糖尿病患者在首次使用 BMF-219 治療後，均表現出臨床活動的早期跡象，β細胞功能測量得到改善
兩名患者對 ...
登入免費觀看全文
登入/註冊